Cagrilintide/Semaglutide Blend 5 mg + 10 mg
Research PeptideCagrilintide + Semaglutide Fixed-Dose Combination Cagrilintide 5mg + Semaglutide 10mg — Research-Grade Dual-Pathway Metabolic Research Blend
Document ID: HKPW-cagrilintide-5-mg-semaglutide-10-mg-rese-v1.0 | Reviewed by: HKPEPTIDE WORLDWIDE Research Team | Last Updated: 2026-08-08
Product Identity & Specifications
| Parameter | Specification |
|---|---|
| Product Name | Cagrilintide + Semaglutide Fixed-Dose Combination |
| Dosage | Cagrilintide 5mg + Semaglutide 10mg |
| CAS Number | 1415456-99-3 / 910463-68-2 |
| Molecular Formula | C₁₈₂H₂₉₃N₄₇O₅₅ / C₁₈₇H₂₉₁N₄₅O₅₉ |
| Molecular Weight | ~4,100.7 / ~4,113.6 Da |
| Sequence | Cagrilintide (amylin analogue) + Semaglutide (GLP-1 agonist) |
| Purity | ≥99% HPLC |
| Appearance | White to off-white lyophilized powder |
| Solubility | Soluble in sterile water or bacteriostatic water |
| Storage | 2–8°C, desiccated, protected from light |
| Classification | Dual-Pathway Metabolic Research Blend |
Research Background
The Cagrilintide + Semaglutide fixed-dose combination is a pre-formulated research blend targeting two independent metabolic pathways: amylin receptor (AMY-R) activation via Cagrilintide and GLP-1 receptor (GLP-1R) activation via Semaglutide. This dual-pathway approach addresses both glucagon suppression (amylin) and insulin secretion enhancement (GLP-1) in a single batch-documented kit. Each peptide component is individually verified by HPLC and MS before combination, and the final product ships with a unified COA covering both peptides. For researchers studying multi-pathway metabolic intervention, this pre-formulated blend eliminates the complexity of separate sourcing, reconstitution, and dose coordination.
The Cagrilintide 5mg + Semaglutide 10mg configuration is manufactured under strict quality control protocols. Each batch undergoes HPLC purity verification, ESI-MS identity confirmation, and amino acid analysis. A batch-specific Certificate of Analysis (COA) is included with every order. Bulk and OEM configurations available for qualifying wholesale accounts.
Molecular Mechanisms
Amylin Pathway (Cagrilintide)
AMY-R activation → postprandial glucagon suppression + delayed gastric emptying + central appetite modulation. Independent of GLP-1R signaling.
GLP-1 Pathway (Semaglutide)
GLP-1R activation → glucose-dependent insulin secretion + gastric emptying delay + hypothalamic satiety signaling. Albumin binding extends half-life to ~7 days.
Dual-Pathway Synergy
Simultaneous AMY-R and GLP-1R activation → complementary effects on glucose homeostasis (glucagon suppression + insulin enhancement) and appetite regulation (dual central signaling). Greater metabolic impact than either pathway alone in preclinical models.
Research Applications
- Dual-Pathway Metabolic Research
- AMY-R + GLP-1R Pharmacology
- Appetite & Satiety Signaling
- Postprandial Glucose Homeostasis
Comparative Analysis
Compared to single-agent protocols: The Cag/Sema blend provides both AMY-R and GLP-1R activation in one kit. Single-agent protocols require separate ordering, reconstitution, and QC management. The pre-formulated blend simplifies multi-pathway research with unified documentation.
Quality Control & Analytical Specifications
| Parameter | Method | Specification |
|---|---|---|
| Purity | HPLC at 214 nm, C18 column | ≥99.0% peak area |
| Identity (MW) | ESI-MS | ~4,100.7 / ~4,113.6 Da |
| Appearance | Visual inspection | White to off-white powder |
| Peptide Content | Amino acid analysis | ≥80% net peptide |
| Residual Moisture | Karl Fischer titration | ≤3% |
| Endotoxin | LAL assay | ≤0.5 EU/mg |
Available Configurations
| Configuration | Content | Best For |
|---|---|---|
| Standard Kit | Cagrilintide 5mg + Semaglutide 10mg × 10 vials | Evaluation; protocol validation |
| Bulk Kit | Custom × 10 vials | Chronic studies; repeat orders |
| OEM/Private Label | Custom | Branded product development |
Frequently Asked Questions
Q: Why combine Cagrilintide and Semaglutide?
They target complementary metabolic pathways. Cagrilintide: amylin receptor → glucagon suppression + appetite. Semaglutide: GLP-1 receptor → insulin secretion + satiety. Together: dual-pathway coverage for comprehensive metabolic research.
Q: Are the peptides co-formulated or separate?
Separate vials in one kit. Each peptide is lyophilized individually under optimized conditions, preserving individual stability profiles. Single COA covers both peptides with one batch number.
Q: What documentation is provided?
Unified COA: individual HPLC purities (≥99% each), individual ESI-MS identities, combined kit batch number. Full analytical package on request.
Tiered Wholesale Pricing
| Volume | Discount | For |
|---|---|---|
| 1 kit | List price | Evaluation; competitive analysis |
| 5+ kits | 10% off | Initial portfolio expansion |
| 20+ kits | 20% off | Mid-size distributors |
| 50+ kits | 30% off | Regional distributors |
Contact our team for 100+ kit custom pricing. Mixed-molecule orders qualify for combined volume tiers.
Related Research & Resources
| Resource | Description |
|---|---|
| Glp 1 Metabolic Peptides Hub | Complete research overview & methodology hub |
| Cagrilintide 5 Mg Semaglutide 10 Mg Rese | Related research peptide product |
| Semaglutide 10 Mg Grade Glp 1 Research P | Related research peptide product |
| Glp 1 Peptides Metabolic Research | Latest research insights & methodology |
View Complete Research Guide »
Compliance Statement
FOR LABORATORY RESEARCH USE ONLY. Not for human or veterinary diagnostic, therapeutic, or prophylactic use. Not a dietary supplement, pharmaceutical ingredient, or approved drug. Researchers must comply with all applicable institutional, local, and national regulations.
© 2026 HKPEPTIDE WORLDWIDE. All rights reserved. Document ID: HKPW-cagrilintide-5-mg-semaglutide-10-mg-rese-v1.0